Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–12 of 12 trials
Active filters
Clinical trials found
Published and searchable clinical trials
NCT05713006
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
- Locations
-
- Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología Mexico City, Mexico
NCT03042221
- Conditions
- ALK Gene Mutation, BRAF V600E, Bronchial Neoplasms, +13 more
- Locations
-
- University of Colorado, Cancer Center Aurora, Colorado, United States
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +12 more
- Locations
-
- Yongchang Zhang Changsha, Hunan, China
NCT06234579
- Conditions
- ALK Gene Mutation, ALK Sensitizing Mutation, Bronchial Neoplasms, +10 more
- Locations
-
- Fondazione Policlinico Gemelli IRCCS Rome, Italy
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
NCT05266846
- Conditions
- ALK Gene Mutation, Adenocarcinoma, Adenocarcinoma of Lung, +10 more
- Locations
-
- Hunan Cancer Hospital Changsha, Hunan, China
- Conditions
- ALK Gene Mutation, Non Small Cell Lung Cancer Metastatic
- Locations
-
- Centro di Riferimento Oncologico (CRO) IRCCS Aviano, Italy
- Azienda Ospedaliero-Universitaria Careggi Oncologia Medica Florence, Italy
- Azienda USL Toscana Nord Ovest Oncologia Medica, Ospedale Versilia Lido di Camaiore, Italy
- Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino amadori" Meldola, Italy
NCT05724004
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +12 more
- Locations
-
- Karolinska University Hospital Stockholm, Sweden
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
NCT07674524
- Conditions
- ALK Gene Mutation, ALK-positive, Bronchial Neoplasms, +16 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
NCT03049618
- Conditions
- ALK Gene Mutation, BRAF Gene Mutation, Bronchial Neoplasms, +25 more
- Locations
-
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
NCT01700582
- Conditions
- ALK Gene Mutation, BRAF Gene Mutation, Bronchial Neoplasms, +10 more
- Locations
-
- Clinique Calabet - Centre de Radiothérapie et d'Oncologie Agen, France
- Clinique Claude Bernard Albi, France
- Clinique de l'Europe Amiens, France
- CHU d'Angers Angers, France
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
NCT05370469
- Conditions
- ALK Gene Mutation, BRAF, EGFR, +13 more
- Locations
-
- University of Virginia Charlottesville, Virginia, United States
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
NCT05200481
- Conditions
- ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
- Locations
-
- CHU d'Angers Angers, France
- CHU Besançon - Hôpital J. MINJOZ Besançon, France
- Hôpital APHP Ambroise Paré Boulogne, France
- Hospices Civils de Lyon - Hôpital Louis Pradel Bron, France